#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Weight Regain After Stopping GLP-1 Drugs
A 2026 Bayesian meta-analysis maps how quickly body weight returns after stopping semaglutide or tirzepatide and what the trajectory looks like over time.
GLP-1 in PCOS: the fertility evidence gaps
A scientific debate in Clinical Nutrition ESPEN spotlights how much the field still does not know about semaglutide, PCOS, and fertility.
Tirzepatide powder: what the label says
Forum questions about reconstituting tirzepatide powder reveal a key fact: FDA-approved tirzepatide is supplied ready-to-inject, not as a lyophilized powder.
Tirzepatide vs care in early T2D at 2 years
A 2-year trial in Annals of Internal Medicine finds tirzepatide reduces HbA1c and weight more than intensified conventional care in early T2D.
Tirzepatide vs semaglutide: meta-analysis
A 2026 meta-analysis in Clinical Obesity pooled head-to-head and indirect trial data comparing tirzepatide and semaglutide for weight loss.
PNPHO nanocarrier for nasal semaglutide
A thermoresponsive PNPHO nanocarrier encapsulated semaglutide at 89% efficiency and improved glucose tolerance in animals. The research is preclinical.
PNPHO nanocarrier for nasal semaglutide
A thermoresponsive PNPHO nanocarrier encapsulated semaglutide at 89% efficiency and improved glucose tolerance in animals. The research is preclinical.
PT-141 for low libido on GLP-1 drugs
Reduced libido is a reported side effect on GLP-1 drugs. Here is what the evidence shows for PT-141 (bremelanotide) and kisspeptin as options for women.
Retatrutide and DKA in type 1 diabetes
A Cureus 2026 case report: a type 1 diabetes patient self-injected online-sourced retatrutide and developed impending DKA alongside a Shigella infection.
Semaglutide and CRP in obesity: 2026 data
A 2026 meta-analysis of nine trials found semaglutide cut body weight 12% and C-reactive protein 41% versus placebo in non-diabetic adults with obesity.
Weight loss as disease modification
A new review asks when reducing excess adiposity changes disease outcomes, and where evidence for semaglutide and tirzepatide remains limited.
GLP-1 drugs in lipedema: survey evidence
A 2026 Obesity Pillars survey collected self-reported outcomes from people with lipedema on GLP-1 or GLP-1/GIP drugs. Patient data, but no controlled trial.